Daily News

Are younger adults more inclined to develop colorectal cancer?

A new study of recent trends in colorectal cancer in the United States confirms that rates among those under the age of 50 years are rising. The findings also reveal that diagnoses of colorectal cancer in younger adults are more likely to be of advanced disease. Using data from the National Cancer Database registry, they found that 12.2% of colorectal cancer diagnoses in the U.S. in 2015 were in people under the age of 50 years compared with 10% in 2004. The vast majority of colorectal cancers are of the adenocarcinoma type. These begin in the cells that make the lubricant, or mucus, that covers the lining of the colon and rectum. Not counting cancers of the skin, of the cancers that doctors diagnose in both women and men in the U.S., colorectal cancer is the third most common, according to the American Cancer Society (ACS). “Because the number of colorectal cancer cases from inherited causes are much higher in younger individuals, it is unknown whether screening for sporadic cases in a group with such low disease rate can result in a favorable balance of harms and benefits."says, Dr. Chyke A. Doubeni. (Source: www.medicalnewstoday.com)

The new strategy of disguising drugs as fats

By using a new technique that disguises anticancer drugs as fats, researchers have managed to safely deliver much higher doses of the drugs than usual to the site of cancer tumors in mouse models. "The drug looks like a nice little fatty acid, so the tumor's receptors see it and invite it in," Prof. Gianneschi explains. "Then the drug starts getting metabolized and kills the tumor cells," he continues. It's like the fatty acid has a hand on both ends: One can grab onto the drug and one can grab onto proteins. The idea is to disguise drugs as fats so that they get into cells and the body is happy to transport them around. "Our goal is to increase the amount that gets into a tumor versus into other cells and tissues. That allows us to dose at much higher quantities without side effects, which kills the tumors faster," Prof. Gianneschi explains. The new research offers hope for more effective and safer methods of delivering anticancer drugs to tumors in human patients.

(Source: www.medicalnewstoday.com)